NCT06972719 Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
| NCT ID | NCT06972719 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | BRCA1 Mutation |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-09-30 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-09-30 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Eligibility Criteria
Inclusion Criteria: * BRCA1 or BRCA2 germline mutation * scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist * premenopausal Exclusion Criteria: * personal history of cancer * postmenopausal * \>50 years old * unable to provide informed consent in English
Contact & Investigator
Laura Havrilesky
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT06972719 clinical trial?
This trial is open to female participants only, aged 19 Years or older, up to 50 Years, studying BRCA1 Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06972719 currently recruiting?
Yes, NCT06972719 is actively recruiting participants. Contact the research team at amelia.lorenzo@duke.edu for enrollment information.
Where is the NCT06972719 trial being conducted?
This trial is being conducted at Chapel Hill, United States, Durham, United States.
Who is sponsoring the NCT06972719 clinical trial?
NCT06972719 is sponsored by Duke University. The principal investigator is Laura Havrilesky at Duke University. The trial plans to enroll 50 participants.